Abstract:Objective To systematically evaluate the relationship between proton pump inhibitors (PPI) and the risk of fractures.Methods The related databases were electronically searched for the cohort studies and the case-control studies about the relationship between proton pump inhibitors and the risk of fractures from inception to July 12, 2016.Meta-analysis were conducted using RevMan 5.3 softwear.The results were presented as odds ratio (OR) or relative risk (RR) and 95% confidence interval (CI).The evidence quality of the enrolled literatures were evaluated by Grades of Recommendation, Assessment, Development, and Evaluation.Results A total of 20 reports which were related to 21 studies involving 9 cohort studies, 12 case-control studies and 2 076 154 subjects were enrolled in the study.There were 262 298 cases who used PPI and 1 813 856 cases who did not use PPI in the 2 076 154 subjects.The pooled results of Meta-analysis of cohort studies showed that compared with the subjects who had not used PPI, the risk of fracture increased 85% in the subjects who used PPI (OR=1.85, 95%CI: 1.55-2.21, P<0.000 01);the risk of hip fracture increased 58% (OR=1.58, 95%CI: 1.07-2.33, P<0.000 01);the risk of fracture in the subjects who were ≥50 years old increased 58% (OR=1.58, 95%CI: 1.47-1.70, P<0.000 01).The pooled results of Meta-analysis after combination of case control studies showed that compared with the subjects who had not used PPI, the risk of fracture increased 39% in the subjects who used PPI (OR=1.39, 95%CI: 1.26-1.52, P<0.000 01);the risk of hip fracture increased 45% (OR=1.45, 95%CI: 1.23-1.69, P<0.000 01);the risk of fracture in the subjects who were ≥50 years old increased 43% (OR=1.43, 95%CI: 1.14-1.79, P=0.002).There were no explicit dose-effect relation and time-effect relation between PPI and hip fracture.The risk of fracture in female and male patients who used PPI increased 110% and 88% as compared with those in female and male patients who never used PPI (OR=2.10, 95%CI: 1.50-2.92, P=0.000 1;OR=1.88, 95%CI: 1.14-3.11, P=0.01), respectively.The result of quality evaluation by GRADE showed that the risk factors (including fracture, hip fracture, female, male, and the patient's age 50-years or older) which increased the degree of fracture after PPI use were all very low quality evidences.Conclusion PPI use modestly could increase the degree of risk of all kinds of fracture and hip fracture, especially in females.

Proton pump inhibitor use and bone fractures in patients with chronic kidney disease

Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients

Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility: A Retrospective Study

Relationship between proton pump inhibitors and the risk of fractures in the observational studies: a systematic review and Meta-analysis

Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved

Proton Pump Inhibitors and the Risk of Bone Fractures: A Systematic Review

An Updated Meta-Analysis: The Effect Of Proton Pump Inhibitor On Risk Of Osteoporosis And Fracture

Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease

Proton Pump Inhibitors and the Risk of Bone Fractures:A Systematic Review

Evidence-based Evaluation of Fracture Risk in Clinical Therapy with Proton Pump Inhibitors

Association between Proton Pump Inhibitor Use and Risk of Incident Chronic Kidney Disease: Systematic Review and Meta-Analysis

Proton Pump Inhibitors and Risk of Hip Fracture: a Systematic Review

Proton pump inhibitors, bone and phosphocalcic metabolism

The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture—results of a large observational cohort study

Association Between Proton Pump Inhibitors Use and Risk of Hip Fracture: A General Population-Based Cohort Study.

Peptic Ulcer Disease and Risk of Hip Fracture: A General Population-based Cohort Study

Proton Pump Inhibitors Therapy and Risk of Hip Fracture

Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank

Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system

PPI use is not associated with bone microarchitecture and strength assessed with HR-pQCT after three-years follow-up in patients visiting the Fracture Liaison Service

The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density